semaglutide and aging A new study from UC San Diego offers early clinical evidence that semaglutide, a widely used GLP-1 receptor agonist, may slow biological aging. In a randomized, placebo-controlled trial, researchers observed a 9% Semaglutide as a possible therapy

"Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies"

I keep an eye on this space because, despite considerable issues with nausea, vomiting, muscle loss, and even rare cases of sudden blindness, the GLP-1 RA drugs may offer the first real hope for patients with metabolic syndrome associated with chronic ulcers

HRAs are funded entirely by your employer and governed by an employer-written plan document that can exclude weight-loss medications, require prior approval, or demand a Letter of Medical Necessity (LMN) before reimbursement

Serious side effects are possible, including liver injury, increased risk for opioid withdrawal, and life threatening opioid intoxication

Following local radiotherapy combined with systemic anlotinib treatment, the patient achieved prolonged progression-free survival (PFS) exceeding 32 months

Appropriate charts were used to graphically present the results whenever needed